Amylyx Pharmaceuticals Target Price

Where could AMLX trade next? Consensus target price: $40.

Get informed when a big investor buys or sells

+ Follow

Share Price

$37.46

Average Target Price

$40.08

7% upside

12 analysts in the last 4 months

High: $55 | Low: $21

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-19	Guggenheim	$55	46.8% upside
2026-08-18	Mizuho SecuritiesGraig Suvannavejh	$42	12.1% upside
2026-08-18	Robert W. Baird	$52	38.8% upside
2026-08-18	H.C. WainwrightAndrew Fein	$55	46.8% upside
2026-08-18	UBS	$55	46.8% upside
2026-08-18	UBS	$45	20.1% upside
2026-08-17	Mizuho SecuritiesGraig Suvannavejh	$30	19.9% downside
2026-08-07	Robert W. Baird	$28	25.3% downside
2026-07-20	Mizuho SecuritiesGraig Suvannavejh	$24	35.9% downside
2026-06-25	Guggenheim	$40	6.8% upside
2026-06-08	H.C. WainwrightAndrew Fein	$34	9.2% downside
2026-04-28	Mizuho SecuritiesGraig Suvannavejh	$21	43.9% downside
2026-02-19	Mizuho Securities	$19	49.3% downside
2026-02-10	H.C. WainwrightAndrew Fein	$28	25.3% downside
2025-10-29	Mizuho Securities	$16	57.3% downside
2025-10-16	Robert W. BairdJoel Beatty	$19	49.3% downside
2025-09-15	GuggenheimSeamus Fernandez	$25	33.3% downside
2025-06-24	GuggenheimSeamus Fernandez	$17	54.6% downside
2025-05-06	Leerink PartnersMarc Goodman	$10	73.3% downside
2024-11-18	Robert W. BairdJoel Beatty	$11	70.6% downside
2024-10-23	Bank of America SecuritiesGeoff Meacham	$10	73.3% downside
2024-10-18	H.C. WainwrightAndrew Fein	$8	78.6% downside
2024-10-18	Leerink PartnersMarc Goodman	$4	89.3% downside
2024-05-14	Mizuho SecuritiesGraig Suvannavejh	$3	92% downside
2024-04-11	Robert W. BairdJoel Beatty	$3	92% downside
2024-04-04	Deutsche BankNeena Bitritto-Garg	$4	89.3% downside
2024-03-17	Mizuho SecuritiesGraig Suvannavejh	$4	89.3% downside

Amylyx Pharmaceuticals (AMLX) FAQ

Amylyx Pharmaceuticals's target price stands at $40. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $40 for AMLX implies 7.0% upside versus today's price ($37.46). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Amylyx Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places AMLX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.